Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.
You may also be interested in...
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.
With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.
Bristol saw a big jump in free Revlimid and Pomalyst provided through patient support programs. It does not expect the issue to persist in 2024, but now expects 2023 revenue to decline rather than grow.